Although glibenclamide has long been a considerable alternative to insulin, recent studies have reported that it can cross the placenta, stimulate fetal insulin secretion, and increase the risks of macrosomia (LGA) and neonatal hypoglycemia in a dose-dependent manner [144,145]. This evidence concerns the gene INS and Hypoglycemia.